Preview

Опухоли головы и шеи

Расширенный поиск

Основные принципы ведения пациентов с мукозитом и дерматитом при лучевом лечении с лекарственной модификацией больных плоскоклеточным раком орофарингеальной области

https://doi.org/10.17650/2222-1468-2016-6-3-22-32

Полный текст:

Аннотация

В работе освещены основные вопросы переносимости лучевого лечения с модификацией пациентов с плоскоклеточным орофарингеальным раком. Представлен спектр побочных эффектов и затронуты ключевые вопросы терапии сопровождения. Отдельно изложены подходы к ведению больных с лучевым мукозитом и дерматитом. 

Об авторах

А. Р. Геворков
Московский научно-исследовательский онкологический институт им. П.А. Герцена – филиал ФГБУ «Национальный медицинский исследовательский радиологический центр» Минздрава России
Россия
125284, Москва, 2-й Боткинский проезд, 3


А. В. Бойко
Московский научно-исследовательский онкологический институт им. П.А. Герцена – филиал ФГБУ «Национальный медицинский исследовательский радиологический центр» Минздрава России
Россия
125284, Москва, 2-й Боткинский проезд, 3


Л. В. Болотина
Московский научно-исследовательский онкологический институт им. П.А. Герцена – филиал ФГБУ «Национальный медицинский исследовательский радиологический центр» Минздрава России
Россия
125284, Москва, 2-й Боткинский проезд, 3


С. В. Шашков
Московский научно-исследовательский онкологический институт им. П.А. Герцена – филиал ФГБУ «Национальный медицинский исследовательский радиологический центр» Минздрава России
Россия
125284, Москва, 2-й Боткинский проезд, 3


Список литературы

1. The Global Burden of Cancer 2013. Global Burden of Disease Cancer Collaboration. JAMA Oncol 2015;1(4):505–27.

2. D’Silva N.J., Ward B.B. Tissue biomarkers for diagnosis & management of oral squamous cell carcinoma. Alpha Omegan 2007;100(4):182–9.

3. Pivot X., Felip E., ESMO Guidelines Working Group. Squamous cell carcinoma of the head and neck: ESMO clinical Recommendations for diagnosis, treatment and follow-up. Ann Оncol 2008;19(Suppl 2):79–80.

4. Состояние онкологической помощи населению России в 2015 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2016. 236 с. [Incidence of malignant neoplasms in Russia in 2015. Eds. by: А.D. Kaprin, V.V. Starinskiy, Moscow, 2016. (In Russ.)].

5. Radiation Oncology: An Evidence-Based Approach. Eds. by J.J. Lu, L.W. Brady. New York: Springer, 2008. 657 p.

6. Pignon et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Rad Oncol 2009:92;4–14.

7. Hansen E.K. Handbook of evidence-based radiation oncology. Eds. by: Eric K. Hansen, Mack III Roach. 2nd ed. Springer, 2010. 786 p.

8. Adelstein D.J., Li Y. et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21(1):92–8.

9. Pignon J.P., Bourhis J. et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACHNC Collaborative Group. Meta￾Analysis of chemotherapy on head and neck cancer. Lancet 2000;355(9208):949–55.

10. Bourhis J., Pignon J.P. et al. Update of MACH-NC (Meta-Analysis of chemotherapy in head & neck cancer) database focused on concomitant chemoradiotherapy. Paper presented at American Society of Clinical Oncology (ASCO) annual meeting, 2004.

11. Calais G., Alfonsi M. et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999;91(24):2081–6.

12. Brizel D.M., Albers M.E. et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338(25):1798–804.

13. Posner M.R., Le Lann L. et al. TAX 324: A phase III trial at TPF vs. PF induction chemotherapy followed chemoradiotherapy in locally advanced SCCHN. Paper presented at American Society of Clinical Oncology (ASCO) annual meeting, Atlanta GA, 2006.

14. Calais G., Alfonsi M. et al. Randomized phase III trial comparing induction chemotherapy using cisplatin (P) fluorouracil (F) with or without docetaxel (T) for organ preservation in hypopharynx and larynx cancer. Preliminary results of GORTEC 2000–01. Paper presented at American Society of Clinical Oncology (ASCO) annual meeting, Atlanta GA, 2006.

15. Bonner J.A., Harari P.M. et al. Radiotherapy plus cetuximab for squamous￾cell carcinoma of the head and neck. N Engl J Med 2006;354(6):567–78.

16. Ang K.K., Zhang Q., Rosenthal D.I. et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol 2014;32:2940–50.

17. Scully С., Epstein J., Sonis S. Oral mucositis: a challenging complication of radiotherapy, chemotherapy and radiochemotherapy. Part 2: Diagnosis and management of mucositis. Head & Neck 2004;1:77–84.

18. Epstein J.B., Thariat J., Bensadoun R.J. Oral complications of cancer and cancer therapy: from cancer treatment to survivorship. CA Cancer J Clin 2012;62(6):400–22.

19. Argiris A., Brockstein B.E., Haraf D.J. et al. Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy. Clin Cancer Res 2004;10:1956–62.

20. Kang H.S., Roh J.L., Lee S. et al. Noncancer-related health events and mortality in head and neck cancer patients after definitive radiotherapy. A Prospective Study. Medicine (Baltimore) 2016;95(19):e3403.

21. Bensinger W. et al. NCCN Task Force Report prevention and management of mucositis in cancer care. J Natl Compr Canc Netw 2008;6(Suppl 1):1–21;22–4.

22. Rosenthal D.I., Trotti A. Strategies for managing radiation-induced mucositis in head and neck cancer. Semin Radiat Oncol 2009;19:29–34.

23. Campos M.I., Campos C.N., Aarestrup F.M., Aarestrup B.J. Oral mucositis in cancer treatment: natural history, prevention and treatment. Mol Clin Oncol 2014;2:337–40.

24. Zhu G. et al. Asian expert recommendation on management of skin and mucosal effects of radiation, with or without the addition of cetuximab or chemotherapy, in treatment of head and neck squamous cell carcinoma. BMC Cancer 2016;16:42.

25. NCCN Guidelines. Version 1. 2016.

26. Mortensen H.R. et al. Factors associated with acute and late dysphagia in the DAHANCA 6 & 7 randomized trial with accelerated radiotherapy for head and neck cancer. Acta Oncol 2013;52:1535–42.

27. Vera-Llonch M. et al. Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma. Cancer 2006;106:329–36.

28. Лучевая терапия злокачественных опу- холей. Руководство для врачей. Под ред. Е.С. Киселевой. М.: Медицина, 1996. 464 с. [Radial therapy of malignant tumors. Manual for physicians. Eds. by Е.S. Kiseleva. Мoscow: Меditsina, 1996. 464 p. (In Russ.)]

29. Сокуренко В.П., Корытова Л.И., Бочкарева Т.Н. Опыт конформной лучевой терапии больных с опухолями орофарингеальной зоны. Медицинская физика 2009;41(1):39. [Sokurenko V.P., Korytovа L.I., Bochkarevа Т.N. Experience of the conformal radiotherapy of patients with oropharyngeal area tumors. Meditsinskaya fizika = Меdical Physics 2009;41(1):39. (In Russ.)].

30. Lalla R.V. Management of oral mucositis in patients with cancer. Eds. by: R.V. Lalla, S.T. Sonis, D.E. Peterson. Dent Clin North Am 2008;52(l):61–7.

31. The impact of dose on parotid salivary recovery in head and neck cancer patients treated with tadiation therapy. Eds. by: Li Y., J.M.G. Taylor, R.K.T. Haken et al. Int J Radiat Oncol Biol Phys 2007;67(3):660–9.

32. Привалов А.В. Осложнения комбинированного лечения злокачественных новообразований и анализ их взаимосвязи. Известия Челябинского научного центра 2003;3(20):125–31. [Privalov А.V. Complication of the combined treatment of malignant tumors and analysis of its mutual relation. Izvestiya Chelyabinskogo nauchnogo tsentra = New of Chelyabinsk Scientific Center 2003;3(20):125–31. (In Russ.)].

33. Цыб А.Ф., Мардынский Ю.С. Терапевтическая радиология. Pуководство для врачей. М.: ООО «МК», 2010. С. 105–160. [Tsyb А.F., Маrdynskiy Yu.S. Тherapeutic radiology: manual for physicians. Моscow: MC LLC, 2010. Pp. 105–160. (In Russ.)].

34. Ярмоненко С.П., Коноплянников А.Г., Вайнсон А.А. Клиническая радиобиология. М.: Медицина, 1992. [Yarmonenko S.P., Konoplyannikov А.G., Vaynson А.А. Clinical radiobiology. Мoscow Меditsina, 1992. (In Russ.)].

35. Roopashri G. Radiotherapy and chemotherapy induced oral mucositis – prevention and current therapeutic modalities. IJDA 2010;2:174–9.

36. Бардычев М.С., Кацалап С.Н. Местные лучевые повреждения: особенности патогенеза, диагностика и лечение. Вопросы онкологии 1995;41(2):99. [Bardy￾chev М.S., Katsalap S.N. Local radial lesions: pathogenesis peculiarities, diagnostics and treatment. Voprosy onkologii = Oncology Issues 1995; 41(2):99. (In Russ.)].

37. Гладилина И.А., Шабанов М.А. Луче- вое и химиолучевое лечение распространенного рака ротоглотки. Тверь, 2001. 110 с. [Gladilinа I.А., Shabanov М.А. Radial and chemoradial treatment of the spread osopharyngeal cancer. Тver, 2001. 110 p. (In Russ.)].

38. Алиева С.Б., Ткачев С.И., Любаев В.Л. и др. Химиолучевая терапия местнораспространенного рака головы и шеи III–IV стадии. Вестник РОНЦ им. Н.Н. Блохина РАМН 2007;18(2):39–42. [Аlievа S.B., Тkachev S.I., Lubaev V.L. et al. Chemoradial therapy of the locally spread head and neck cancer of III–IV stage. Herald of N.N. Blokhin Russian Cancer Research Center RAMS 2007;18(2):39–42. (In Russ.)].

39. Бойко A.B., Голдобенко Г.В., Канаев С.В. и др. Современная лучевая терапия: достижения и перспективы. Вопросы онкологии 1995;41(2):83–90. [Boykо, A.V., Goldobenkо G.V., Kanaev S.V. et al. Modern radial therapy: achievements and prospects. Voprosy onkologii = Oncology issues 1995;41(2):83–90. (In Russ.)].

40. Harris R. et al. Radiotherapy skin care: A survey of practice in the UK. Radiography 2011. DOI: 10.1016/j.radi.2011.10.040.

41. Bernier J. et al. Management of radiation dermatitis in patients receiving cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: proposals for a revised grading system and consensus management guidelines. Ann Oncol 2011;22:2191–200.

42. Hymes S.R. et al. Radiation dermatitis: clinical presentation, pathophysiology, and treatment. J Am Acad Dermatol 2006;54:28–46.

43. Бардычев М.С., Шукашвили Н.Н. Клинико-морфологическая характеристика поздних лучевых язв кожи. Медицинская радиология 1974;(6):32–7. [Bardychev М.S., Shujashvili N.N. Clinical & morphological characteristics of the delayed skin radiation ulcers. Meditsinskaya radiologiya = Меdical Radiology 1974;(6):32–7. (In Russ.)].

44. Хосева Е.Н., Малишееская Н.П., Берзин С.А. Дерматологические последствия лучевой терапии онкологических больных. Альманах клинической медицины 2006:9:154–9. [Hosevа Е.N., Маlisheeskaya N.P., Berzin S.А. Dermatologic consequences of the radial therapy of oncologic patients. Al’manakh klinicheskoy meditsiny = Clinical Medicine Almanac 2006:9:154–9. (In Russ.)].

45. Сопроводительная терапия в онкологии. Практическое руководство. Под ред. С.Ю. Мооркрафта, Д.Л.Ю. Ли, Д. Каннингэма. Пер. с англ. Под ред. А.Д. Каприна. М.: ГЭОТАР-Медиа, 2016. 432 с. [Accompanying therapy in oncology. Practical manual. Eds. by: S.Yu. Moorcraft, D.L.Yu. Lee, D. Cunningham. Translated from English. Edu. by А.D. Kaprin. Мoscow: GEOTAR-Media, 2016. 432 p. (In Russ.)].

46. Brady O., Donnelly M., Horgan A., Maher M. Post-radiotherapy side effects for head and neck cancer – the patient’s perspective. Proceedings of the Nutrition Society. Harrogate; P. 283.

47. Galloway T., Amdur R. Management and prevention of complications during initial treatment of head and neck cancer. Eds. by: M. Posner, B. Brockstein, D. Brizel, D. Deschler. Up To Date, Waltham, MA, 2014.

48. Langius J.A., Zandbergen M.C., Van Tulder M.W. et al. Effect of nutritional interventions on nutritional status of patients with head and neck cancer receiving (chemo) radiotherapy: a systematic review. Clin Nutr 2013;32:671–8.

49. Payakachat N., Ounpraseuth S., Suen J.Y. Late complications and long-term quality of life for survivors (> 5 years) with history of head and neck cancer. Head Neck 2013;35:819–25.

50. Paleri V., Roe J.W.G., Strojan P. et al. Strategies to reduce long-term postchemoradiation dysphagia in patients with head and neck cancer: An evidence-based review: Strategies to reduce dysphagia after chemoradiation. Head Neck. 2014;36:431–43.

51. Wendt T.G., Grabenbauer G.G., Rodel C.M. et al: Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 1998;16:1318–24.

52. Gamelin E., Allain P., Maillart P. et al. Long term pharmacokinetic behavior of platinum after cisplatin administration. Cancer Chemother Pharmacol 1995; 37:97–102.

53. Trotti A., Bellm L.A., Epstein J.B. et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: A systematic literature review. Radiother Oncol 2003;66:253–62.

54. Machtay M., Moughan J., Trotti A. et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: An RTOG analysis. J Clin Oncol 2008;26:3582–9.

55. Практические рекомендации по лекарственному лечению злокачественных опухолей (RUSSCO). Под ред. В.М. Моисеенко. М.: ООО «Российское общество клинической онкологии», 2015. 456 с. [Practical recommendations on the pharmaceutical treatment of malignant tumors (RUSSCO). Eds. by: V.М. Моiseenko. Мoscow; Russian Clinical Oncology Society LLC, 2015. 456 p. (In Russ.)].

56. Bonner J.A. et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11:21–8.

57. Curran D. et al. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with Cetuximab. Clin Oncol 2007;25:2191–7.

58. Russi E.G. et al. Bio-radiation dermatitis: the need of a new grading: in regard to Bernier et al: Ann Oncol 2011;22(10):2191–200. Ann Oncol 2013;24:2463–5.

59. Pinto et al. Management of skin toxicity associated with Cetuximab treatment in combination with chemotherapy or radiotherapy. Oncologist 2011;16:228–38.

60. Cowart B.J. Taste dysfunction: a practical guide for oral medicine. Oral Diseases 2011;17(1):2–6.

61. Elad S., Zadik Y., Hewson I. A systematic review of viral infections associated with oral involvement in cancer patients: a spotlight on Herpes viridea. Supp Care in Cancer 2010;18(8):993–1006.

62. Roopashri G. Radiotherapy and chemotherapy induced oral mucositis – prevention and current therapeutic modalities. IJDA 2010;2:174–9.

63. Georgiou M., Patapatiou G., Domoxoudis S. et al. Oral Mucositis: understanding the pathology and management. Hippokratia 2012;16:215–6.

64. Pauloski B.R. Rehabilitation of dysphagia following head and neck cancer. Phys Med Rehabil Clin N Am 2008;9:889–928.

65. McQuestion M. Evidence-based skin care management in radiation therapy. Semin Oncol Nurs 2006;22:163–73.

66. Feight D., Baney T., Bruce S., McQuestion M. Putting evidence into practice. Clin Oncol Nurs 2011; 15:481–92.

67. Schnur J.B., Quellette S.C., DiLorenzo T.A. et al. A qualitative analysis of acute skin toxicity among breast cancer radiotherapy patients. Psycho-Oncology 2011;20:260–8.

68. Горбунова В.А., Бредер В.В. Качество жизни онкологических больных. Матери- алы 4-й Российской онкологической конференции М., 2000. С. 125–127. [Gorbunovа V.А., Breder V.V. Life quality of oncologic patients. Маterials of the 4th Russian Oncologic Conference Мoscow, 2000. Pp. 125–127 (In Russ.)].

69. Husaini H., Lazarus C., Hu K. et al. EORTC QOL rating, performance status, and oral outcomes in head-and-neck cancer patients treated with chemoradiation therapy. Int J Radiat Oncol Biol Phys 2013;87:441–2.

70. Kumari A.C., Shanmughakumar S., Balasubramaniam P. Assessment of quality of life in head and neck cancer patients with enteral tube feeding. J Cancer Res Therapeutic 2012;8:S176.

71. Mourad W.F., Hu K.S., Puckett L. et al. Five-year outcomes of squamous cell carcinoma of the tonsil treated with radiotherapy. Am J Clini Oncol 2014; 37:57–62.

72. Prevost V., Joubert C., Heutte N., Babin E. Assessment of nutritional status and quality of life in patients treated for head and neck cancer. Eur Ann Otorhinolaryngol Head Neck Dis 2014;131:112–20.


Для цитирования:


Геворков А.Р., Бойко А.В., Болотина Л.В., Шашков С.В. Основные принципы ведения пациентов с мукозитом и дерматитом при лучевом лечении с лекарственной модификацией больных плоскоклеточным раком орофарингеальной области. Опухоли головы и шеи. 2016;6(3):12-21. https://doi.org/10.17650/2222-1468-2016-6-3-22-32

For citation:


Gevorkov A.R., Boykо A.V., Bolotinа L.V., Shashkov S.V. Basic principles of managing radiation and drug induced mucositis and dermatitis for oropharyngeal squamouscell carcinoma. Head and Neck Tumors (HNT). 2016;6(3):12-21. (In Russ.) https://doi.org/10.17650/2222-1468-2016-6-3-22-32

Просмотров: 295


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2222-1468 (Print)
ISSN 2411-4634 (Online)